Clinical trial
A Pilot Study of Gut Microbiome Modulation to Enable Efficacy of Checkpoint-based Immunotherapy in Pancreatic Adenocarcinoma
NCT03891979 is registered in ClinicalTrials.gov with NYU Langone Health as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Pilot Study of Gut Microbiome Modulation to Enable Efficacy of Checkpoint-based Immunotherapy in Pancreatic Adenocarcinoma
- Lead sponsor
- NYU Langone Health
- Phase
- Phase 4
- Overall status
- Withdrawn
- Start date
- June 25, 2019
- Completion date
- June 1, 2020
- Enrollment
- 0 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
pancreatic cancer